Drugs /

reparixin

Back to Drugs List

Overview

NCI Definition [1]:
An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration, reparixin allosterically binds to CXCR1 and prevents CXCR1 activation by its ligand interleukin 8 (IL-8 or CXCL8). This may cause cancer stem cell (CSC) apoptosis and may inhibit tumor cell progression and metastasis. CXCR1, overexpressed on CSCs, plays a key role in CSC survival and the ability of CSC to self-renew; it is also linked to tumor resistance to chemotherapy. Inhibition of the IL-8/CXCR1 interaction also potentiates the cytotoxic effect of chemotherapeutic agents. In addition, reparixin inhibits CXCR2 activation and may reduce both neutrophil recruitment and vascular permeability during inflammation or injury.

Clinical Trials

View Clinical Trials for reparixin

Reparixin has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating reparixin, 1 is phase 2 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for reparixin clinical trials.

Breast carcinoma is the most common disease being investigated in reparixin clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Reparixin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating reparixin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
266359-83-5, df 1681y, 2-(4-isobutylphenyl)propionylmethanesulfonamide, benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-n- (methylsulfonyl)- (alphar)-, reparixin, repertaxin, repertaxin, 2-(4-isobutylphenyl)propionylmethanesulfonamide, (r)-2-(4-isobutylphenyl)propionylmethanesulfonamide
Drug Target(s) [2]:
CXCR1, CXCR2
NCIT ID [1]:
C66515

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.